The Addition of Lipid-Based Contrast Medium does not Inactivate the Detergent Sclerosant Sodium Tetradecyl Sulfate in-vitro.
Arteriovenous malformations
Lymphatic malformations
Sclerotherapy
Sodium tetradecyl sulfate
Vascular malformations
Venous malformations
Journal
Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
27
08
2020
accepted:
03
02
2021
pubmed:
13
3
2021
medline:
13
7
2021
entrez:
12
3
2021
Statut:
ppublish
Résumé
To investigate if the detergent sclerosant sodium tetradecyl sulfate (STS) is deactivated by the lipid-based contrast agent ethiodised oil. 3% STS was mixed with ethiodised oil and room air in a 2:1:4 ratio in two luer lock syringes and a three way connector and agitated to make foam (the Tessari technique) to replicate the clinical use of the products. The assay of STS in the mixture was assessed using the British Pharmacopoeia method. Briefly this is a manual titration method where the solution of STS is mixed with an indicator solution and titrated with hyamine solution of known concentration; the concentration of the STS can then be calculated with the titration results. To further mimic the clinical environment with the presence of blood, the effect of adding increasing amounts of albumin to the STS-ethiodised oil mixture was assessed. The assay of STS in the solution after mixing with ethiodised oil was 3% indicating that the ethiodised oil did not deactivate the STS. The addition of albumin to the STS-contrast mixture resulted in near linear neutralisation of the STS with increasing concentrations in the same quantities as with STS alone. The mixture of the lipid-based contrast agent ethiodised oil with the detergent sclerosant STS did not affect the availability of the sclerosant. The continued use of STS-ethiodised oil in the management of vascular malformations can be supported.
Identifiants
pubmed: 33709269
doi: 10.1007/s00270-021-02797-2
pii: 10.1007/s00270-021-02797-2
doi:
Substances chimiques
Contrast Media
0
Sclerosing Solutions
0
Ethiodized Oil
8008-53-5
Sodium Tetradecyl Sulfate
Q1SUG5KBD6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1103-1108Références
Horbach SE, Lokhorst MM, Saeed P, deGouyonMatignondePontouraude CM, Rothova A, vanderHorst CM. Sclerotherapy for low-flow vascular malformations of the head and neck a systematic review of sclerosing agents. J Plast Reconstr Aesthet Surg. 2016;69:295–304. https://doi.org/10.1016/j.bjps.2015.10.045 .
doi: 10.1016/j.bjps.2015.10.045
pubmed: 26723834
Hage AN, Chick JFB, Srinivasa RN, Bundy JJ, Chauhan NR, Acord M, et al. Treatment of Venous Malformations: The Data, Where We Are, and How It Is Done. Tech Vasc Interv Radiol. 2018;21:45–54. https://doi.org/10.1053/j.tvir.2018.03.001 .
doi: 10.1053/j.tvir.2018.03.001
pubmed: 29784122
Cabrera J, Cabrera J Jr, Garcia-Olmedo MA, Redondo P. Treatment of venous malformations with sclerosant in microfoam form. Arch Dermatol. 2003;139:1409–16. https://doi.org/10.1001/archderm.139.11.1409 .
doi: 10.1001/archderm.139.11.1409
pubmed: 14623700
Pascarella L, Bergan JJ, Yamada C, Mekenas L. Venous angiomata: treatment with sclerosant foam. Ann Vasc Surg. 2005;19:457–64. https://doi.org/10.1007/s10016-005-4656-z .
doi: 10.1007/s10016-005-4656-z
pubmed: 15981122
Yamaki T, Nozaki M, Fujiwara O, Yoshida E. Duplex-guided foam sclerotherapy for the treatment of the symptomatic venous malformations of the face. Dermatol Surg. 2002;28:619–22.
pubmed: 12135522
Orsini C, Brotto M. Immediate pathologic effects on the vein wall of foam sclerotherapy. Dermatol Surg. 2007;33:1250–4. https://doi.org/10.1111/j.1524-4725.2007.33261.x .
doi: 10.1111/j.1524-4725.2007.33261.x
pubmed: 17903159
Kok K, McCafferty I, Monaghan A, Nishikawa H. Percutaneous sclerotherapy of vascular malformations in children using sodium tetradecyl sulphate: the Birmingham experience. J Plast Reconstr Aesthet Surg. 2012;65:1451–60. https://doi.org/10.1016/j.bjps.2012.05.005 .
doi: 10.1016/j.bjps.2012.05.005
pubmed: 22717975
Parsi K. Interaction of detergent sclerosants with cell membranes. Phlebology. 2015;30:306–15. https://doi.org/10.1177/0268355514534648 .
doi: 10.1177/0268355514534648
pubmed: 24827732
Watkins MR. Deactivation of sodium tetradecyl sulphate injection by blood proteins. Eur J Vasc Endovasc Surg. 2011;41:521–5. https://doi.org/10.1016/j.ejvs.2010.12.012 .
doi: 10.1016/j.ejvs.2010.12.012
pubmed: 21262579
British Pharmacopoeia Commission. British Pharacopoeia 2019. London: TSO; 2019.
Acord M, Srinivasan AS, Cahill AM. Percutaneous Treatment of Lymphatic Malformations. Tech Vasc Interv Radiol. 2016;19:305–11. https://doi.org/10.1053/j.tvir.2016.10.001 .
doi: 10.1053/j.tvir.2016.10.001
pubmed: 27993327
Ali S, Weiss CR, Sinha A, Eng J, Mitchell SE. The treatment of venous malformations with percutaneous sclerotherapy at a single academic medical center. Phlebology. 2016. https://doi.org/10.1177/0268355516633380 .
doi: 10.1177/0268355516633380
pubmed: 27009607
Bourgouin P, Thomas-Chausse F, Gilbert P, Giroux MF, Perigny S, Guertin L, et al. Effectiveness and Safety of Sclerotherapy for Treatment of Low-Flow Vascular Malformations of the Oropharyngeal Region. J Vasc Interv Radiol. 2018;29:809–15. https://doi.org/10.1016/j.jvir.2017.12.028 .
doi: 10.1016/j.jvir.2017.12.028
pubmed: 29628299
Bundy JJ, Hage AN, Chick JFB, Srinivasa RN, Gemmete JJ. Balloon and Coil Occlusion of a Superior Sagittal Sinus Cortical Vein Facilitates Percutaneous Supraorbital Venous Malformation Sclerotherapy. Cardiovasc Intervent Radiol. 2018;41:1112–5. https://doi.org/10.1007/s00270-018-1948-6 .
doi: 10.1007/s00270-018-1948-6
pubmed: 29600422
Chick JF, VanBelkum A, Yu V, Majdalany BS, Khaja MS, Cooper KJ, et al. Balloon-Occluded Retrograde Abdominal Lymphangiography and Embolization for Opacification and Treatment of Abdominal Chylous Leakage. J Vasc Interv Radiol. 2017;28:616–8. https://doi.org/10.1016/j.jvir.2016.11.044 .
doi: 10.1016/j.jvir.2016.11.044
pubmed: 28343590
Chiramel GK, Keshava SN, Moses V, Mammen S, David S, Sen S. Percutaneous sclerotherapy of congenital slow-flow vascular malformations of the orbit. Cardiovasc Intervent Radiol. 2015;38:270–9. https://doi.org/10.1007/s00270-014-0971-5 .
doi: 10.1007/s00270-014-0971-5
pubmed: 25148921
Damodaran O, McAuliffe W, Wong G, McCloskey E, Lee G. Preoperative sclerotherapy using sodium tetradecyl sulphate (fibro-vein) can assist in the management of vertebral hemangiomas. Global Spine J. 2012;2:169–74. https://doi.org/10.1055/s-0032-1315451 .
doi: 10.1055/s-0032-1315451
pubmed: 24353964
pmcid: 3864480
Delgado J, Bedoya MA, Gaballah M, Low DW, Cahill AM. Percutaneous sclerotherapy of foot venous malformations: evaluation of clinical response. Clin Radiol. 2014;69:931–8. https://doi.org/10.1016/j.crad.2014.04.014 .
doi: 10.1016/j.crad.2014.04.014
pubmed: 24865314
Eliasson JJ, Weiss I, Hogevold HE, Oliver N, Andersen R, Try K, et al. An 8-year population description from a national treatment centre on lymphatic malformations. J Plast Surg Hand Surg. 2017;51:280–5. https://doi.org/10.1080/2000656X.2016.1254092 .
doi: 10.1080/2000656X.2016.1254092
pubmed: 27846771
Guevara CJ, Gonzalez-Araiza G, Kim SK, Sheybani E, Darcy MD. Sclerotherapy of Diffuse and Infiltrative Venous Malformations of the Hand and Distal Forearm. Cardiovasc Intervent Radiol. 2016;39:705–10. https://doi.org/10.1007/s00270-015-1277-y .
doi: 10.1007/s00270-015-1277-y
pubmed: 26678548
Harmoush S, Chinnadurai P, El Salek K, Metwalli Z, Herce H, Bhatt A, et al. Multimodality Image-Guided Sclerotherapy of Low-Flow Orbital Vascular Malformations: Report of Single-Center Experience. J Vasc Interv Radiol. 2016;27(987–95):e4. https://doi.org/10.1016/j.jvir.2016.02.036 .
doi: 10.1016/j.jvir.2016.02.036
Kuhara A, Tanaka N, Kugiyama T, Koganemaru M, Kiyokawa K, Abe T. Treatment of a large pharyngeal venous malformation using transoral sclerotherapy. Kurume Medical Journal. 2017;64:35–8.
doi: 10.2739/kurumemedj.MS640014
Leung M, Leung L, Fung D, Poon WL, Liu C, Chung K, et al. Management of the low-flow head and neck vascular malformations in children: the sclerotherapy protocol. Eur J Pediatr Surg. 2014;24:97–101. https://doi.org/10.1055/s-0033-1354585 .
doi: 10.1055/s-0033-1354585
pubmed: 24008546
Mukund A, Deogaonkar G, Rajesh S, Shasthry SM, Sarin SK. Safety and Efficacy of Sodium Tetradecyl Sulfate and Lipiodol Foam in Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) for Large Porto-Systemic Shunts. Cardiovasc Intervent Radiol. 2017;40:1010–6. https://doi.org/10.1007/s00270-017-1593-5 .
doi: 10.1007/s00270-017-1593-5
pubmed: 28180928
Nassiri N, Huntress LA, Simon M, Murphy S. An institution-wide algorithm for direct-stick embolization of peripheral venous malformations. J Vasc Surg Venous Lymphat Disord. 2018;6:351–7. https://doi.org/10.1016/j.jvsv.2017.12.011 .
doi: 10.1016/j.jvsv.2017.12.011
pubmed: 29396158
Scorletti F, Patel MN, Hammill AM, Ricci KW, Myer CMt, Dasgupta R, . Sclerotherapy for intramuscular vascular malformations: A single-center experience. J Pediatr Surg. 2018;53:1056–9. https://doi.org/10.1016/j.jpedsurg.2018.02.040 .
doi: 10.1016/j.jpedsurg.2018.02.040
pubmed: 29519571
Stimpson P, Hewitt R, Barnacle A, Roebuck DJ, Hartley B. Sodium tetradecyl sulphate sclerotherapy for treating venous malformations of the oral and pharyngeal regions in children. Int J Pediatr Otorhinolaryngol. 2012;76:569–73. https://doi.org/10.1016/j.ijporl.2012.01.019 .
doi: 10.1016/j.ijporl.2012.01.019
pubmed: 22341629
Stuart S, Barnacle AM, Smith G, Pitt M, Roebuck DJ. Neuropathy after sodium tetradecyl sulfate sclerotherapy of venous malformations in children. Radiology. 2015;274:897–905.
doi: 10.1148/radiol.14132271
Tahir M, Mumtaz MA, Sultan A, Iqbal J, Sayani R. Role of Interventional Radiology in the Management of Peripheral Vascular Malformations: A Tertiary Care Center Experience. Cureus. 2018;10:e2335. https://doi.org/10.7759/cureus.2335 .
doi: 10.7759/cureus.2335
pubmed: 29774173
pmcid: 5955714
Tan KT, Kirby J, Rajan DK, Hayeems E, Beecroft JR, Simons ME. Percutaneous sodium tetradecyl sulfate sclerotherapy for peripheral venous vascular malformations: a single-center experience. J Vasc Interv Radiol. 2007;18:343–51. https://doi.org/10.1016/j.jvir.2006.12.735 .
doi: 10.1016/j.jvir.2006.12.735
pubmed: 17377179
Tessari L. Nouvelle technique d’obtenion de la sclero-mousse. Phlebologie. 2000;53:129.
Dabbs EB, Dos Santos SJ, Mainsiouw LE, Sheikh AA, Gkantiragas A, Shiangoli I, et al. Implication of foam sclerosant inactivation by human whole blood in a laboratory setting. Phlebology. 2018;33:338–43. https://doi.org/10.1177/0268355517708468 .
doi: 10.1177/0268355517708468
pubmed: 28516808
Thibault PK. Sclerotherapy of varicose veins and telangiectasias: A 2-year experience with sodium tetradecyl sulphate. Aust N Z J Phlebol. 1999;3:25–30.
Bush R, Bush P. Evaluation of sodium tetradecyl sulfate and polidocanol as sclerosants for leg telangiectasia based on histological evaluation with clinical correlation. Phlebology. 2017;32:496–500. https://doi.org/10.1177/0268355516673768 .
doi: 10.1177/0268355516673768
pubmed: 27738241
Kobayashi S, Crooks S, Eckmann DM. Dose- and time-dependent liquid sclerosant effects on endothelial cell death. Dermatol Surg. 2006;32:1444–52. https://doi.org/10.1111/j.1524-4725.2006.32350.x .
doi: 10.1111/j.1524-4725.2006.32350.x
pubmed: 17199651
Guex JJ. Complications and side-effects of foam sclerotherapy. Phlebology. 2009;24:270–4. https://doi.org/10.1258/phleb.2009.009049 .
doi: 10.1258/phleb.2009.009049
pubmed: 19952383
Rabe E, Breu FX, Cavezzi A, Coleridge Smith P, Frullini A, Gillet JL, et al. European guidelines for sclerotherapy in chronic venous disorders. Phlebology. 2014;29:338–54. https://doi.org/10.1177/0268355513483280 .
doi: 10.1177/0268355513483280
pubmed: 23559590
Rabe E, Pannier F. Sclerotherapy in venous malformation. Phlebology. 2013;28(Suppl 1):188–91. https://doi.org/10.1177/0268355513477282 .
doi: 10.1177/0268355513477282
pubmed: 23482557
Hafner F, Froehlich H, Gary T, Brodmann M. Intra-arterial injection, a rare but serious complication of sclerotherapy. Phlebology. 2013;28:64–73. https://doi.org/10.1258/phleb.2011.011155 .
doi: 10.1258/phleb.2011.011155
pubmed: 22422795